Changjiang Pharmaceutical Group Co., Ltd. (SHE:300391)
China · Delayed Price · Currency is CNY 0.1900
0.00 (0.00%)
Inactive · Last trade price on Apr 10, 2026
SHE:300391 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
| 67 | 1,766 | 2,712 | 3,416 | 5,325 | 4,299 | |
Market Cap Growth | -96.15% | -34.88% | -20.61% | -35.85% | 23.88% | 68.78% |
Enterprise Value | 659 | 3,276 | 4,459 | 5,371 | 6,765 | 4,176 |
Last Close Price | 0.19 | 5.04 | 7.74 | 9.75 | 15.20 | 12.27 |
Price Ratios
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
PE Ratio | - | - | - | - | 108.44 | 169.77 |
Forward PE | - | 14.67 | 14.67 | 14.67 | 14.67 | 14.67 |
PS Ratio | 0.57 | 15.82 | 2.26 | 2.12 | 2.26 | 3.54 |
PB Ratio | -0.10 | -4.19 | 2.67 | 2.05 | 3.31 | 2.97 |
P/TBV Ratio | - | - | - | 40.91 | 86.06 | 2069.26 |
P/FCF Ratio | - | - | - | - | 60.02 | 307.38 |
P/OCF Ratio | - | - | - | - | 23.05 | 131.03 |
EV Ratios
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
EV/Sales Ratio | 5.68 | 29.35 | 3.72 | 3.33 | 2.86 | 3.44 |
EV/EBITDA Ratio | - | - | - | 28.82 | 21.91 | 34.30 |
EV/EBIT Ratio | - | - | - | 65.22 | 26.94 | 53.02 |
EV/FCF Ratio | -3.76 | - | - | - | 76.25 | 298.61 |
Financial Efficiency
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Debt / Equity Ratio | -0.96 | -2.84 | 1.20 | 0.61 | 0.59 | 0.69 |
Debt / EBITDA Ratio | - | - | - | 5.16 | 3.06 | 8.15 |
Debt / FCF Ratio | - | - | - | - | 10.72 | 70.95 |
Net Debt / Equity Ratio | -0.93 | -2.82 | 1.18 | 0.60 | 0.52 | 0.59 |
Net Debt / EBITDA Ratio | -0.81 | -1.63 | -11.82 | 5.38 | 2.73 | 7.00 |
Net Debt / FCF Ratio | -3.53 | -14.96 | -7.81 | -8.52 | 9.51 | 60.94 |
Asset Turnover | 0.05 | 0.04 | 0.34 | 0.42 | 0.53 | 0.39 |
Inventory Turnover | 1.96 | 2.55 | 18.44 | 10.11 | 8.21 | 4.34 |
Quick Ratio | 0.45 | 0.55 | 1.02 | 0.97 | 0.80 | 0.66 |
Current Ratio | 0.50 | 0.59 | 1.13 | 1.13 | 0.98 | 0.81 |
Return on Equity (ROE) | -4036.87% | -482.81% | -52.75% | 2.72% | 10.42% | 6.02% |
Return on Assets (ROA) | -19.77% | -17.49% | -2.46% | 1.32% | 3.53% | 1.59% |
Return on Invested Capital (ROIC) | - | -66.40% | -5.67% | 2.00% | 10.56% | 5.47% |
Return on Capital Employed (ROCE) | 287.00% | -1071.00% | -8.80% | 4.00% | 11.90% | 3.80% |
Yields
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Earnings Yield | -986.61% | -35.57% | -22.34% | -0.68% | 0.92% | 0.59% |
FCF Yield | -263.30% | -4.50% | -5.69% | -3.44% | 1.67% | 0.33% |
Payout Ratio | - | - | - | - | 76.03% | 50.98% |
Buyback Yield / Dilution | -0.00% | 0.00% | 0.05% | -0.07% | -0.01% | 0.04% |
Total Shareholder Return | -0.00% | 0.00% | 0.05% | -0.07% | -0.01% | 0.04% |